|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
1990
|
|
gptkbp:ATCCode
|
P01CX03
|
|
gptkbp:boilingPoint
|
decomposes
|
|
gptkbp:brand
|
gptkb:Ornidyl
gptkb:Vaniqa
|
|
gptkbp:CASNumber
|
700-13-0
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
|
|
gptkbp:developedBy
|
Merrell Dow
|
|
gptkbp:discoveredBy
|
Irwin H. S. Gelbard
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:form
|
crystalline powder
|
|
gptkbp:halfLife
|
3 hours
|
|
gptkbp:hasInChIKey
|
QKQKRCQVRVQKQR-REOHCLBHSA-N
|
|
gptkbp:hasMolecularFormula
|
C6H12F2N2O2
|
|
gptkbp:hasSMILES
|
C(C[C@@H](C(=O)O)N)N(CF)F
|
|
gptkbp:hasUNII
|
4I6E4J345W
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DFMO
|
|
gptkbp:IUPACName
|
(2R)-2-difluoromethylornithine
|
|
gptkbp:KEGGID
|
D07913
|
|
gptkbp:legalStatus
|
prescription only
off-patent
Rx-only
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:mechanismOfAction
|
irreversible inhibitor of ornithine decarboxylase
|
|
gptkbp:meltingPoint
|
220-222 °C
|
|
gptkbp:molecularWeight
|
182.17 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (AU)
|
|
gptkbp:PubChem_CID
|
CHEMBL1387
30815
DB01140
|
|
gptkbp:routeOfAdministration
|
topical
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
diarrhea
hearing loss
seizures
gastrointestinal disturbances
|
|
gptkbp:solubility
|
water soluble
|
|
gptkbp:synonym
|
Eflornithine
α-difluoromethylornithine
|
|
gptkbp:target
|
gptkb:ornithine_decarboxylase
|
|
gptkbp:therapeuticArea
|
gptkb:disease
dermatology
|
|
gptkbp:usedFor
|
treatment of African trypanosomiasis
treatment of facial hirsutism
|
|
gptkbp:bfsParent
|
gptkb:eflornithine
|
|
gptkbp:bfsLayer
|
6
|